年龄相关性黄斑变性
Age-related macular degeneration.
作者信息
Guymer Robyn H, Campbell Thomas G
机构信息
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Department of Surgery (Ophthalmology), The University of Melbourne, Melbourne, VIC, Australia.
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia; Department of Surgery (Ophthalmology), The University of Melbourne, Melbourne, VIC, Australia; Department of Ophthalmology, Sunshine Coast University Hospital, Sunshine Coast, QLD, Australia.
出版信息
Lancet. 2023 Apr 29;401(10386):1459-1472. doi: 10.1016/S0140-6736(22)02609-5. Epub 2023 Mar 27.
Age-related macular degeneration is an increasingly important public health issue due to ageing populations and increased longevity. Age-related macular degeneration affects individuals older than 55 years and threatens high-acuity central vision required for important tasks such as reading, driving, and recognising faces. Advances in retinal imaging have identified biomarkers of progression to late age-related macular degeneration. New treatments for neovascular age-related macular degeneration offer potentially longer-lasting effects, and progress is being made towards a treatment for atrophic late age-related macular degeneration. An effective intervention to slow progression in the earlier stages of disease, or to prevent late age-related macular degeneration development remains elusive, and our understanding of underlying mechanistic pathways continues to evolve.
由于人口老龄化和寿命延长，年龄相关性黄斑变性已成为一个日益重要的公共卫生问题。年龄相关性黄斑变性影响55岁以上的个体，并威胁到阅读、驾驶和人脸识别等重要任务所需的高敏锐度中心视力。视网膜成像技术的进步已确定了晚期年龄相关性黄斑变性进展的生物标志物。新生血管性年龄相关性黄斑变性的新疗法可能具有更持久的效果，并且在萎缩性晚期年龄相关性黄斑变性的治疗方面也取得了进展。在疾病早期阶段减缓进展或预防晚期年龄相关性黄斑变性发展的有效干预措施仍然难以捉摸，我们对潜在机制途径的理解也在不断发展。
Zotero 插件